Cue Biopharma reports positive Phase 2 topline results for CUE-221
Cue Biopharma said CUE-221 met dose-responsive primary and secondary endpoints in chronic spontaneous urticaria, with a favorable safety profile and durable benefit versus placebo and omalizumab.
Key Highlights:Original SEC Filing: Cue Biopharma, Inc. [ CUE ] - 8-K - Sep. 21, 2026This is an AI-powered su…